loading...| Preferred Name |
New compounds (for the castrate resistant status only) |
|
| Synonyms |
|
|
| Definitions |
During castration, the occurrence of castration-resistant status (CRPC) is systematic. It is thought that it is mediated through two main overlapping mechanisms, which are androgen-receptor (AR)-independent and AR-dependent (see Section 6.11 - Castrate-resistant Prostate Cancer). In CRPC, the intracellular androgen level is increased compared to androgen sensitive cells, and an over-expression of the AR has been observed in CRPC, suggesting an adaptative mechanism. This has led to the development of two new major compounds targeting the androgen axis: abiraterone acetate and enzalutamide. |
|
| ID |
http://www.semanticweb.org/ontologies/2018/1/ProstateCancer.owl#New_compounds_(for_the_castrate_resistant_status_only) |
|
| ChineseLabel |
新化合物（仅用于去势抵抗状态） |
|
| definition |
During castration, the occurrence of castration-resistant status (CRPC) is systematic. It is thought that it is mediated through two main overlapping mechanisms, which are androgen-receptor (AR)-independent and AR-dependent (see Section 6.11 - Castrate-resistant Prostate Cancer). In CRPC, the intracellular androgen level is increased compared to androgen sensitive cells, and an over-expression of the AR has been observed in CRPC, suggesting an adaptative mechanism. This has led to the development of two new major compounds targeting the androgen axis: abiraterone acetate and enzalutamide. |
|
| label |
New compounds (for the castrate resistant status only) |
|
| prefLabel |
New compounds (for the castrate resistant status only) |
|
| subClassOf |
http://www.semanticweb.org/ontologies/2018/1/ProstateCancer.owl#Hormonal_therapy |